Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 12Neoplasm Metastasis 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence Free Survival 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Histiocytosis 1Fallopian Tube Neoplasms 1Erythema 1Endometrial Neoplasms 1Edema 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Paclitaxel 23Carboplatin 20Bevacizumab 20liposomal doxorubicin 14Specimen Handling 14olaparib 13Magnetic Resonance Spectroscopy 13Topotecan 9Gemcitabine 9Biopsy 8pembrolizumab 7Taxes 7Immunoglobulin G 7Disulfides 7cediranib 5niraparib 4mirvetuximab soravtansine 4Doxorubicin 4oregovomab 3Nivolumab 3Cyclophosphamide 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Oxaliplatin 2Docetaxel 2Cisplatin 2Biosimilar Pharmaceuticals 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Panitumumab × 90 days × Clear all
NCT05564377 2026-06-12

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡